clinical trial · NCT06690242
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
Shaanxi Micot Pharmaceutical Technology Co., Ltd.·phase2·completed·n = 115
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisMT1013MT1013Etelcalcetide HydrochloridePlacebo
brief summary
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.
started
Nov 4, 2024
primary completion
Oct 15, 2025
completion
Oct 15, 2025
last updated
Feb 5, 2026
official title
A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol